Back
AnaptysBio, Inc. 10K Form
Buy
60
ANAB
AnaptysBio, Inc.
Last Price:
$60.51
Seasonality Move:
-7.42%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2023-11-02 | 10Q | ANAB/AnaptysBio, Inc. Quarterly |
| 2023-08-07 | 10Q | ANAB/AnaptysBio, Inc. Quarterly |
| 2023-05-11 | 10Q | ANAB/AnaptysBio, Inc. Quarterly |
| 2022-11-08 | 10Q | ANAB/AnaptysBio, Inc. Quarterly |
| 2022-08-08 | 10Q | ANAB/AnaptysBio, Inc. Quarterly |
| 2022-05-04 | 10Q | ANAB/AnaptysBio, Inc. Quarterly |
Receive ANAB News And Ratings
See the #1 stock for the next 7 days that we like better than ANAB
ANAB Financial Statistics
Sales & Book Value
| Annual Sales: | $91.3M |
|---|---|
| Cash Flow: | $98M |
| Price / Cash Flow: | 92.49 |
| Annual Sales: | $1.33 |
| Price / Book: | 45.06 |
Profitability
| EPS (TTM): | -0.52060 |
|---|---|
| Net Income (TTM): | $-13.2M |
| Gross Margin: | $88.9M |
| Return on Equity: | -97.37% |
| Return on Assets: | -3.38% |
AnaptysBio, Inc. Earnings Forecast
Key AnaptysBio, Inc. Financial Ratios
-
The Gross Profit Margin over the past 5 years for ANAB is 97.37%.
-
The Selling, General & Administrative Expenses for ANAB have been equal to 46.44% of Gross Profit Margin.
-
The Research & Development expenses have been 178.83% of Revenue.
-
The Net Earning history of ANAB is -159.10% of Total Revenues.
-
Per Share Earnings over the last 12 years have been positive in 4 years.
AnaptysBio, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | ANAB |
| CUSIP: | 032724 |
| Website: | anaptysbio.com |
Debt
| Debt-to-Equity Ratio: | 7.81 |
|---|---|
| Current Ratio: | 9.07 |
| Quick Ratio: | 8.94 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
ANAB Technical Analysis vs Fundamental Analysis
Buy
60
AnaptysBio, Inc. (ANAB)
is a Buy
Is AnaptysBio, Inc. a Buy or a Sell?
-
AnaptysBio, Inc. stock is rated a BuyThe current AnaptysBio, Inc. [ANAB] share price is $60.55. The Score for ANAB is 60, which is 20% above its historic median score of 50, and infers lower risk than normal.